Kornimate/medical-research-clean huggingface dataset:
pulmonary gas exchange abnormalities in patients with mild copd

Conditions: COPD

Summary: people with mild chronic obstructive pulmonary disease (copd) can have significant physiological abnormalities and breathing inefficiency which become more pronounced during the stress of exercise, leading to intolerable breathing discomfort (dyspnea). to better understand the mechanisms of respiratory symptoms and exercise limitation in mild copd, we will examine detailed lung function tests and other important measurements during rest and exercise in people with mild copd compared with healthy non-smokers. this will be the first study to uncover the fundamental causes of breathing inefficiency and the related shortness of breath during physical exertion in patients with mild copd. we hope to demonstrate that one simple measurement during exercise \[the relation (ratio) between the total amount of air breathed (ventilation) and the amount of carbon dioxide breathed out\] gives meaningful information about the extent of damage to the small airways and blood vessels in mild copd and the overall gas exchanging function of the lungs, without the need for an arterial blood sample. this is a case-controlled observational study not involving an intervention. participants will complete 2 visits approximately 1 week apart, each conducted at the same time of day. visit 1 will consiste of screening for iligibility, symptom and activity assessments, pulmonary function tests and an incremental cycle cardiopulmonary exercise test (cpet) for familiarization purposes. visit 2 will include spirometry followed by an incremental cycle cpet with detailed measures of ventilatory, gas exchange, sensory-perceptual and arterial blood gas responses.


Eligibility criteria:
inclusion criteria: * stable symptomatic patients with gold grade 1b mild copd; * at least 50 years of age; * a cigarette smoking history ≥20 pack-years; * a baseline dyspnea index focal score ≤9; * post-bronchodilator forced expiratory volume in 1 second (fev1) ≥80 %predicted and an fev1/forced vital capacity (fvc) ratio \<0.7 and \< lower limit of normal. exclusion criteria: * clinically significant comorbidities; * contraindications to exercise testing; * history/clinical evidence of asthma; * body mass index \ 30 kg/m2; * use of supplemental oxygen.

Keywords: exercise
comparison of intermittent oro-esophageal tube feeding in infants with cerebral palsy and dysphagia

Conditions: Cerebral Palsy

Summary: this was a randomized controlled study including 80 infants with cerebral palsy and dysphagia. the participants were evenly divided into the observation group (with intermittent oro-esophageal tube feeding, n=40) and the control group (with persistent nasogastric tube feeding , n=40). nutritional status and physical development, condition of dysphagia, and pneumonia before and after 3-month treatment were compared.

in china, for nutrition support in the infants under one year of age with cerebral palsy and dysphagia, persistent nasogastric tube feeding is the mainstream choice. however, the efficacy of persistent nasogastric tube feeding is not sufficiently satisfactory, necessitating the exploration for a more effective and safe nutrition support approach. therefore, this study reports the clinical effect of intermittent oro-esophageal tube feeding compared to persistent nasogastric tube feeding in the infants with cerebral palsy and dysphagia who received systemic therapy. method this was a randomized controlled study including 80 infants with cerebral palsy and dysphagia. the participants were evenly divided into the observation group (with intermittent oro-esophageal tube feeding, n=40) and the control group (with persistent nasogastric tube feeding, n=40). nutritional status and physical development, condition of dysphagia, and pneumonia before and after 3-month treatment were compared.

Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of cerebral palsy formulated by the 13th national conference on pediatric cerebral palsy rehabilitation; * age\<1 year; * diagnosed as dysphagia confirmed by dysphagia disorder survey or pediatric esophagoscopy; * with a nasogastric tube inserted at admission; * enteral nutrition support is required and feasible. exclusion criteria: * with dysphagia caused by other diseases or factors; * with progressive neurological disease or degenerative neurological disease; * with severe heart disease, liver or kidney dysfunction, hematological disorders, or other acute and severe symptoms; * with abnormalities in the oral cavity, pharynx, esophagus, or other parts of the digestive tract; * with poor compliance.
multi-target pallidal and thalamic deep brain stimulation for hemi-dystonia

Conditions: Dystonia; Dystonia, Secondary

Summary: dystonia is increasingly being considered as a multi-nodal network disorder involving both basal ganglia and cerebellar dysfunction. the aim of this study is to determine if "multi-target" thalamic and pallidal deep brain stimulation improves hemi-dystonia patients who are receiving inadequate therapy from gpi dbs.


Eligibility criteria:
inclusion criteria: 1. diagnosed with hemi-dystonia secondary to stroke 2. candidate for gpi dbs 3. able to provide informed consent exclusion criteria: 1. history of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms) that may account for dystonia or essential tremor. 2. history or evidence of ongoing psychiatric or neurodegenerative disorders (such as parkinson's disease, alzheimer's disease). 3. incompetent adults or those unable to communicate.
cardiac output assessment by using saline contrast injection

Conditions: Echocardiography

Summary: cardiac output (co) assessment is one of the cornerstone of hemodynamic evaluation in icu patients. co is usually measured using invasive methods or non-invasive methods. thermodilution is considered as the gold standard for co assessment. cardiac doppler as well demonstrated to be accurate but needs manipulations and good knowledge and skills. the investigators developed a new technique using injection of agitated saline solution to evaluate co without any manual measurement and then observer independent.

the investigators decided to conduct a prospective observational study to compare contrast assessment of co and cardiac doppler technique. patients hospitalized in icu will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). patients with swan ganz catheter will be included as well. cardiac output will be measured using cardiac doppler. simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. this solution will be injected as usual and echocardiographic imaging will be recorded. these imaging will be analyzed off-line and co will be calculated with an algorithm previously developed and compared with the reference method. in case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.

Eligibility criteria:
inclusion criteria: * all icu patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test. exclusion criteria: * patients under 18 years old * pregnant patients * moribund patients

Keywords: echocardiography doppler cardiac output contrast thermodilution agitated saline icu
role of agvhd biomarkers on agvhd risks

Conditions: GVHD,Acute; Biomarker

Summary: to establish risk rating criteria of biological protein marker, determine the role and consistency of agvhd biomarkers in agvhd diagnosis and agvhd prognosis, and evaluate the the impact on non-relapse mortality and relapse and disease free survival, the multicenter study on agvhd biomarkers detection in the patients underwent allogeneic hematopoietic stem cell transplantation was performed.

1. to establish standard risk rating criteria of agvhd biomarkers; 2. to verify the role of agvhd biomarkers monitored in predicting agvhd risks; 3. to determine the correlation between agvhd biomarkers monitored and agvhd risk; 4. to carry out a observative study in patients with agvhd treatment about therapeutic protocols and medication efficacy; 5. to predict the correlation between the high-risk patients with agvhd and non-relapse mortality and disease free survival;

Eligibility criteria:
inclusion criteria: 1. diagnosed with hematological diseases. 2. have underwent first allogeneic hematopoietic stem cell transplantation (allo-hsct) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. exclusion criteria: 1. recipients of second allogeneic stem cell transplant. 2. pregnant or breast-feeding women. 3. serum creatinine \> 2.0 mg/dl or creatinine clearance \< 40 ml/min measured or calculated by cockroft-gault equation. 4. human immunodeficiency virus infection 5. active hepatitis b virus, hepatitis c virus infection and need antivirus treatment. 6. subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-hsct was performed, or graft rejection. 7. allergic history to janus kinase inhibitors. 8. severe organ dysfunction unrelated 9. any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
a safety study of live attenuated varicella vaccines in healthy adults, adolescents and children

Conditions: Varicella

Summary: the purpose of this study is to evaluate the safety of a live attenuated varicella vaccine in healthy adults, adolescents, and children.

this study is a randomized, blind, single-center, controlled phase i clinical trial. the purpose of this study is to evaluate the safety of a live attenuated varicella vaccine manufactured by sinovac (dalian) vaccine technology co., ltd. the positive control is a commercialized live attenuated varicella vaccine manufactured by shanghai institute of biological products co., ltd. (sibp), and the negative control is diluent of lyophilized vaccine manufactured by sinovac (dalian) vaccine technology co., ltd. all participants are healthy, and will be randomly assigned into experimental group, positive control group, or negative control group in the ratio 1:1:1.

Eligibility criteria:
inclusion criteria: * healthy volunteer between 1 - 49 years old; * proven legal identity; * guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study; exclusion criteria: * prior vaccination with varicella vaccine or with history of varicella zoster virus (vzv) infection; * axillaty temperature \> 37.0 °c; * breast feeding, pregnant, or expected to conceive during the period of this trial; * history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; * history of epilepsy, seizures or convulsions, or a family history of mental illness; * autoimmune disease or immunodeficiency; * severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases; * acute disease or acute stage of chronic disease within 7 days prior to study entry; * receipt of any of the following products: 1. any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 2. any live attenuated vaccine within 1 month prior to study entry; 3. any blood product, immunosuppressant, hormone, or other investigational medicine(s) within 30 days prior to study entry; * any significant abnormity of heart, lung, skin, or pharynx; * any of the pre-immune test results of the following indexes of laboratory tests showed clinically significant abnormity: 1. blood routine examinations: hemoglobin (hb), white blood cells (wbc) count; 2. blood biochemistry detections: alanine transferase (alt), total bilirubin, blood urea nitrogen (bun), creatinine; 3. urine routine tests: urine protein, urine glucose, urine erythrocyte * any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;

Keywords: live attenuated varicella vaccine safety adult adolescent child
effects of an exercise program for nursing home patients with dementia

Conditions: Dementia

Summary: the purpose of this study is to investigate the effect of an exercise program on nursing home patients with dementia.

the intervention group will be exercising one hour twice a week for 12 weeks. the participants will be doing intensive strength exercises and challenging balance exercises in groups of 4-6. two physical therapists will be leading the intervention group. the control group will be meeting at the same frequency. groups of 4-6 will be lead by an occupational therapist. the participants will be doing relaxation exercises, listen to music and social activities such as board games or indoor bowling. the investigators will carry out three test periods: * baseline testing before intervention start * post test after 12 weeks of intervention * follow-up 12 weeks after post test. the testing will comprise: * physical tests carried out by physiotherapists * questionnaires concerning mental health and adl (activities of daily living) * cognition tests * cortisol in saliva

Eligibility criteria:
inclusion criteria: * \>55 years old * living in nursing home * able to stand with help from max 1 * able to walk 6 meters with or without walking aid exclusion criteria: * medically unstable * longterm psychotic * severe communication problems

Keywords: exercise dementia nursing home
randomized controlled trial comparing embryonic quality in rfsh versus hmg in ivf protocol with gnrh antagonist

Conditions: Infertility

Summary: rfsh and hmg are both used to controlled ovarian stimulation for patients submitted to ivf. however, there is a debate in the literature which one is better to induce ovulation in patients receiving gnrh antagonist to block premature luteinizing hormone (lh) secretion. the investigators propose a randomized clinical trial (rct) to investigate the differences among recombinant fsh and hmg in patients submitted to ivf using gnrh antagonists.

to compare embryonic quality and other clinical outcomes when using human menopause gonadotropin (hmg) or recombinant follicle stimulating hormone (rfsh) to the ovarian stimulation in ivf cycles with the gnrh antagonist protocol. design: open randomized single center study with infertile patients submitted to ivf comparing ivf outcomes between hmg and rfsh when controlled with gnrh antagonist. setting: a single private center of reproductive medicine in association with universidade federal do rio grande do sul. patients: infertile women with normal ovarian reserve with ivf indication. intervention: the patients were randomized in two groups, 85 received rfsh and 83 received hmg to ovulation induction, both groups used gnrh antagonist to prevent ovulation. main outcome measure: total embryonic score and best embryonic score. secondary outcomes: total dose of gonadotropins, number and size of follicles in the end of the stimulation, number of mature oocytes, number of embryos, pregnancy rates.

Eligibility criteria:
inclusion criteria: * 25 to 40 y * infertile * submitted to ivf * no hormonal disease * normal fsh (\< 10) * anti-mullerian hormone (amh) \> 1 ng and \< 10 ng * both ovaries * only first or second ivf exclusion criteria: * thyroid-stimulating hormone (tsh), prolactin (prl) altered * endometrioma * ovarian tumor or cysts * previous ovarian hyperstimulation syndrome (ohss) * severe male factor

Keywords: follicular stimulating hormone human menopausal gonadotrophin recombinant follicular stimulating hormone (rfsh) gonadotrophin releasing hormone (gnrh) antagonists gnrh agonist in vitro fertilization controled ovarian stimulation number of mature oocytes
eye screening in german secondary diabetes care centers

Conditions: Diabetic Retinopathy

Summary: in patients with confirmed diagnosis of diabetes, an eye examination and a comprehensive survey are conducted after recruitment in secondary diabetes care centers. all patients undergo a comprehensive eye examination including wide-angle fundus photograph and ocular cohaerence tomography. a questionnaire assesses the characteristics (history: diabetes duration, type of treatment), knowledge and personal attitudes of the persons affected. the relevant lab findings were collected from the electronic files. main focus of the study is the concordance to the national screening recommendations (last eye exam, presence of retinopathy).


Eligibility criteria:
inclusion criteria: - diabetes exclusion criteria: * mental handicap * in the case of blindness absence of a caregiver
systolic time intervals a prognostic tool of heart failure in emergency departement (sti/ahf)

Conditions: Dyspnea; Heart Failure

Summary: the performance of stis and clinical scores alone and their combination to predict short term prognosis of acute decompensated heart failure.

acute heart failure is a leading cause of hospitalization and death.prediction of these adverse events is still challenging. sti is an old technique based on the recording of two parameters: electrocardiogram and phonocardiogram, and from them measuring the different systolic intervals: pre-ejection period (pep),electro-mechanic activation time (emat), left ventricular ejection time (lvet) and systolic time ratio (rts) were measured. the aim of these study is to demonstrate whether systolic time intervals (stis) can improve clinical scores effect (enhanced feedback for effective cardiac treatment) and gwtg-hf (get with the guidelines-heart failure) for predicting 30 day mortality and readmission in patients with acute decompensated heart failure (adhf) in the ed.

Eligibility criteria:
inclusion criteria: * non traumatic dyspnea * age more than 18 years old. exclusion criteria: * ecg diagnostic for acute myocardial infarction * ischemic chest pain within the prior 24 hours * history of a heart transplant * pericardial effusion * chest wall deformity suspected of causing dyspnea * coma * shock,mechanical ventilation, vasopressor drugs * arrhythmia serious and sustained, * pace maker * severe mitral valve disease, * severe pulmonary arterial hypertension * renal failure with creatinine \>350micromol/l

Keywords: impedance dyspnea ahf bnp effect gwtg-hf
evaluation of neuroprosthesis with sensory feedback for modulation of phantom limb pain and enhancing quality of life

Conditions: Phantom Limb Pain

Summary: this clinical trial is designed to assess the effectiveness of advanced neuromodulation techniques in reducing phantom limb pain by improving sensory feedback in bionic prostheses. the study will explore the use of peripheral nerve stimulation to evaluate their impact on pain relief and sensory restoration. the trial aims the development of neuroprostheses that can provide sensory feedback through stimulation.


Eligibility criteria:
inclusion criteria: * amputation of the upper limb at the level of the forearm or upper arm, or amputation of the lower limb at the level of the lower leg or thigh. * age between 18 and 65 years. * duration since amputation is at least 6 months. * presence of persistent chronic pain syndrome rated between 4 and 10 on the visual analog scale (vas). * absence of pregnancy at the time of implantation, confirmed by a pregnancy test (for female participants only). * signed consent to participate in the study. exclusion criteria: * presence of severe somatic pathology that hinders surgical treatment and participation in the study. * presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts. * presence of severe orthopedic deformity in the limb above the level of amputation. * history of cancer. * history of epilepsy. * complicated traumatic brain injury (tbi) or a history of stroke. * inability to undergo electrostimulation due to other somatic pathology. * purulent-septic pathology. * drug addiction (including a history of). * congenital anomaly of upper limb development. * anomalies in the development of the central and peripheral nervous systems.

Keywords: neuromodulation phantom limb pain neuropathic pain neurostimulation chronic pain peripheral nerve stimulation pns spinal cord stimulation scs dorsal root ganglion stimulation drg cortical stimulation amputation neurotechnology neuroprosthetics bci
echo-doppler assessment of the occurrence of asymptomatic dvt in orthopedic replacement surgery under enoxaparin

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Adverse Effect of Anticoagulants

Summary: the objectives of the study are: o objective ultrasound: determine the presence or absence of subclinical dvt in practicing ultrasound-doppler day7 and day35, patients who underwent tka or tha o clinical objective to evaluate the efficacy and tolerability clinical enox ® in these patients compared with the original drug lovenox ®.


Eligibility criteria:
inclusion criteria: * man or woman aged over 18 years, admitted to undergo orthopedic total knee or total hip prosthesis requiring the use of enoxaparin 4000 iu for the prophylaxis. exclusion criteria: * patient participating in another study. * hypersensitivity to enoxaparin sodium, heparin unfractionated heparin or other low molecular weight. * patients at risk of major bleeding or uncontrolled including patients with recent stroke * pregnant

Keywords: deep veinous thrombosis enoxaparin
study of factors predicting tumor recurrence after liver transplantation for hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma; Liver Cirrhosis; Evidence of Liver Transplantation

Summary: results of liver transplantation, the best theoretical treatment for hcc, are limited by tumor recurrence. in order to limit this risk milan criteria was proposed in 1996. however, these criteria are to restrictive and approximately 40% of patients denied by milan criteria may be cured by liver transplantation. the purpose of this study was thus to prospectively evaluate factors predicting tumor recurrence after liver transplantation for hcc and then to reassess criteria for liver transplantation.

in this study, the investigators studied the predictive value of imaging techniques such as ct, mri, pet scan, of serological markers and molecular markers assessed before liver transplantation at listing. the investigators also evaluated the predictive value of tumor growing during the waiting time (imaging and serological). finally, the investigators compared pre-lt data and explanted liver analysis to evaluate accuracy of liver biopsy and of imaging.

Eligibility criteria:
inclusion criteria: * liver cirrhosis * hepatocellular carcinoma diagnosed by aasld criteria or liver biopsy * listing for liver transplantation for hcc fulfilling or not milan criteria * no extra-hepatic spread * no vascular involvement exclusion criteria: * salvage transplantation * transplantation contra-indication * evaluation for liver transplantation older than 1 month * incidental hcc

Keywords: hepatocellular carcinoma cirrhosis transplantation